VEGFs (vascular endothelial growth factors) are master regulators of vascular development and of blood and lymphatic vessel function during health and disease in adults. This family of five mammalian ligands acts through three RTKs (receptor tyrosine kinases). In addition, co-receptors such as NRPs (neuropilins) associate with the ligand–receptor signalling complex and modulate the output. Therapeutics to block several of the VEGF signalling components as well as NRP function have been developed with the aim of halting blood vessel formation, angiogenesis, in diseases that involve tissue growth and inflammation, such as cancer. The present review outlines the current understanding of NRPs in relation to blood and lymphatic vessel biology.
Conference Article| January 19 2012
Neuropilin signalling in angiogenesis
Sina Koch 1
1Department of Immunology, Genetics and Pathology (IGP), Rudbeck Laboratory, Uppsala University, Dag Hammarskjöldsväg 20, 75185 Uppsala, Sweden
1Present address: Department of Systemic Cell Biology, Max Planck Institute of Molecular Physiology, Otto-Hahn-Strasse II, 44227 Dortmund, Germany (email Sina.Koch@mpi-dortmund.mpg.de).
Search for other works by this author on:
- Views Icon Views
- Share Icon Share
- Cite Icon Cite
Sina Koch; Neuropilin signalling in angiogenesis. Biochem Soc Trans 1 February 2012; 40 (1): 20–25. doi: https://doi.org/10.1042/BST20110689
Download citation file: